A Case of Severe Liver Dysfunction During the Administration of Alectinib-Reference-Cited by-同舟云学术

A Case of Severe Liver Dysfunction During the Administration of Alectinib

Published:2019-08-20 Issue:4 Volume:59 Page:354-359
ISSN:0386-9628
Container-title:Haigan
language:en
Short-container-title:JJLC

Author:

Tani Tetsuo¹,Fukui Takahiro¹,Sunata Keeya¹,Funatsu Yohei¹,Kaneko Kotaro²,Koh Hidefumi¹

Affiliation:

1. Division of Pulmonary Medicine, Department of Internal Medicine, Federation of National Public Service Personnel Mutual Aid Associations, Tachikawa Hospital

2. Division of Gastroenterology, Department of Internal Medicine, Federation of National Public Service Personnel Mutual Aid Associations, Tachikawa Hospital

Publisher

Japan Lung Cancer Society

Subject

Pulmonary and Respiratory Medicine,Oncology

Link

https://www.jstage.jst.go.jp/article/haigan/59/4/59_354/_pdf

Reference9 articles.

1. 2. Seto T, Kiura K, Nishio M, Nakagawa K, Maemondo M, Inoue A, et al. CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1-2 study. Lancet Oncol. 2013; 14: 590-598.

2. 4. Sun JM, Choi YL, Won JK, Hirsch FR, Ahn JS, Ahn MJ, et al. A dramatic response to crizotinib in a non-small-cell lung cancer patient with IHC-positive and FISH-negative ALK. J Thorac Oncol. 2012; 7: e36-e38.

3. 7. Gadgeel SM, Gandhi L, Riely GJ, Chiappori AA, West HL, Azada MC, et al. Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study. Lancet Oncol. 2014; 15: 1119-1128.

4. 8. Hida T, Nokihara H, Kondo M, Kim YH, Azuma K, Seto T, et al. Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial. Lancet. 2017; 390: 29-39.

5. 10. Ferrari C, Penna A, Bertoletti A, Valli A, Antoni AD, Giuberti T, et al. Cellular immune response to hepatitis B virus-encoded antigens in acute and chronic hepatitis B virus infection. J Immunol. 1990; 145: 3442-3449.